Savara (NASDAQ:SVRA) Price Target Lowered to $6.00 at HC Wainwright

Savara (NASDAQ:SVRA - Get Free Report) had its price objective dropped by investment analysts at HC Wainwright from $10.00 to $6.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 84.62% from the stock's previous close.

Other analysts also recently issued research reports about the company. JMP Securities reiterated a "market outperform" rating and issued a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI restated an "in-line" rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.17.

Savara Stock Performance

SVRA stock traded down $0.58 during mid-day trading on Wednesday, hitting $3.25. The stock had a trading volume of 3,171,763 shares, compared to its average volume of 1,211,222. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. Savara has a 1-year low of $3.24 and a 1-year high of $5.70. The company has a fifty day moving average of $3.96 and a 200 day moving average of $4.22.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). As a group, sell-side analysts expect that Savara will post -0.44 EPS for the current fiscal year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently modified their holdings of SVRA. Bain Capital Life Sciences Investors LLC boosted its stake in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company's stock valued at $72,536,000 after buying an additional 332,706 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock worth $32,874,000 after purchasing an additional 4,157,385 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock worth $28,547,000 after buying an additional 1,001,296 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Savara by 2.5% during the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company's stock worth $30,197,000 after buying an additional 148,673 shares in the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in shares of Savara by 198.2% during the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock worth $20,879,000 after buying an additional 3,443,541 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.